These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14866256)

  • 1. [Therapeutic value of a new anticoagulant: the ethyl ester of di-3,3'-(4-oxycoumarinyl) acetic acid].
    LIAN C; SIGUIER F; WELTI JJ; COBLENTZ B; NEDEY ; BREYNAERT
    Sem Hop; 1951 May; 27(35):1511-22. PubMed ID: 14866256
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacological properties and physiological effects of a new anticoagulant: the ethyl ester of di-3,3'-(4-oxycoumarinyl) acetic acid].
    LIAN C; SIGUIER F; WELTI JJ; PIETTE M; POULLAIN P; PHILIPPON J
    Sem Hop; 1951 May; 27(35):1505-11. PubMed ID: 14866255
    [No Abstract]   [Full Text] [Related]  

  • 3. [A case of ingestion of ethyl ester of bis-4-oxycoumarinyl acetic acid (tromexan) in suicide attempt].
    CATALANO V; NAVAZIO F
    Prog Med (Napoli); 1956 May; 12(9):274-5. PubMed ID: 13336168
    [No Abstract]   [Full Text] [Related]  

  • 4. [Metabolism in rats following prolonged administration of pelentan (di 4-hydroxycumarinyl-3-acetic acid ethylester); studies on anticoagulant substances V].
    HAIS IM; ZABRODSKY S
    Cas Lek Cesk; 1950 Oct; 89(40):1116-20. PubMed ID: 14772872
    [No Abstract]   [Full Text] [Related]  

  • 5. [Use of anticoagulants in dermatology; use of tromexan (ethyl ester of di-4-hydroxy-coumarinyl acetic acid) in ulcus cruris in dystrophy with thrombophlebitis and in related conditions].
    PANCONESI E
    Rass Dermatol Sifilogr; 1951; 4(2):74-105. PubMed ID: 14892261
    [No Abstract]   [Full Text] [Related]  

  • 6. [A new synthetic anticoagulant, the ethyl ester of dioxycoumarinyl-acetic acid or tromexan].
    BICKEL G; DELLA SANTA R
    Rev Med Suisse Romande; 1949 Sep; 69(9):545-58. PubMed ID: 18140885
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical experiences with the anticoagulant, ethyl biscoumacetate (N.N.R.).
    BARKER NW; ESTES JE; MANN FD
    Proc Staff Meet Mayo Clin; 1951 Apr; 26(9):162-7. PubMed ID: 14827945
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacology of bis 3-3'-(4 oxycoumarinyl) ethyl acetate (tromexan).
    STIRLING M; HUNTER RB
    Lancet; 1951 Oct; 2(6684):611-4. PubMed ID: 14874456
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical observations on the use of the ethyl ester of 4-4'-dioxy-cumarinyl acetic acid as an anticoagulant].
    BIFANI I; CASOLO P
    Policlinico Prat; 1950 Nov; 57(46):1481-7. PubMed ID: 14797463
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experimental study on the ethyl ester of bis-3-3'-(4-oxidocumarinyl)-acetic acid as an anticoagulant].
    CASTEX MR; PAVLOVSKY A; CASTELLANOS H; de MITTELMAN DG
    Prensa Med Argent; 1950 Jul; 37(30):1695-1701. PubMed ID: 15440620
    [No Abstract]   [Full Text] [Related]  

  • 11. [The ethyl ester of di- (4-oxycumarinyl) acetic acid and the biological characteristics of its anticoagulant activity].
    DE NICOLA P
    Farmaco Sci Tec; 1949; 4(2):152-60. PubMed ID: 18130201
    [No Abstract]   [Full Text] [Related]  

  • 12. [Control of anticoagulant effect of (bis-(4-oxycumarinyl)-3,3')-ethyl ester of acetic acid by determination of factor VII].
    DE NICOLA P
    Klin Wochenschr; 1952 Jun; 30(21-22):512. PubMed ID: 12981819
    [No Abstract]   [Full Text] [Related]  

  • 13. [Tromexan and marcoumar in anticoagulant therapy; micromethod for determination of prothrombin-proconvertin activity].
    IVERSEN T
    Ugeskr Laeger; 1955 Jul; 117(27):873-8. PubMed ID: 13256759
    [No Abstract]   [Full Text] [Related]  

  • 14. [A new synthetic anticoagulant; Tromexan (G 11705)].
    DELLA SANTA R
    Schweiz Med Wochenschr; 1949 Mar; 79(9):195-206. PubMed ID: 18115607
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical evaluation of dicumarinyl derivatives with a metabolic study of the radioactively labeled anticoagulants in animals.
    HAUSNER EP; SHAFER CL; CORSON M; JOHNSON O; TRUJILLO T; LANGHAM W
    Circulation; 1951 Feb; 3(2):171-81. PubMed ID: 14812645
    [No Abstract]   [Full Text] [Related]  

  • 16. Anticoagulant therapy with tromexan and marcoumar and determination of the prothrombin-proconvertin activity by a micro-method.
    IVERSEN T
    Acta Med Scand; 1956 Sep; 155(3):161-70. PubMed ID: 13361829
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical experience with the anticoagulant, tromexan.
    BRONSTEIN MR; WITKIND E
    Am J Med Sci; 1951 Dec; 222(6):677-85. PubMed ID: 14885211
    [No Abstract]   [Full Text] [Related]  

  • 18. [PAPER CHROMATOGRAPHIC DEMONSTRATION OF THE ANTICOAGULANTS 3-(1-PHENYLPROPYL)-4-HYDROXYCOUMARIN (FALITHROM) AND THE ETHYL ESTER OF DIHYDROXYCOUMARINYLACETIC ACID (PELENTAN)].
    FROST E; SEIDLEIN HJ
    Pharm Prax; 1964; 204():28-33. PubMed ID: 14235737
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical results with tromexan, a new anticoagulant].
    von KAULLA KN
    Dtsch Med Wochenschr; 1950 Sep; 75(38):1259-62. PubMed ID: 14773354
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical trials with a new anticoagulant; tromexan].
    MILANES B; HERNANDEZ A; PEREZ STABLE E
    Rev Cubana Cardiol; 1951; 12(4):141-50. PubMed ID: 12994207
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.